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ABSTRACT
Introduction: Dipeptidyl peptidase-4 (DPP-4)
inhibitors are widely used in the management
of patients with type 2 diabetes mellitus (T2DM)
and renal impairment (RI). A systematic
literature review was performed to compare
the efficacy and safety of DPP-4 inhibitors in
patients with T2DM and RI.
Methods: We searched EMBASE, MEDLINE, and
the Cochrane Central Register of Controlled
Trials (cut-off, June 2015) to identify C12-week,
randomized, placebo-controlled trials on DPP-4
inhibitors in C50 patients with T2DM and RI.
Outcomes of interest included change in
glycated hemoglobin (HbA1c), overall safety,
and incidence of hypoglycemic events (HEs).
Results: Seven trials of B52–54 weeks duration
were retrieved, which included one study each
on vildagliptin, saxagliptin, and sitagliptin, two
on linagliptin, and the remaining two were
extension studies of vildagliptin and
saxagliptin. Majority of patients were on
insulin at baseline (53–86%), except in the
sitagliptin study, where approximately 11%
received insulin during the placebo-controlled
phase. After 52 weeks, vildagliptin and
saxagliptin reduced HbA1c levels by 0.6–0.7%
(baseline 7.8–8.4%) versus placebo in the
overall population. HbA1c reductions were
similar at weeks 12 and 52. In the 12-week,
placebo-controlled phase, sitagliptin and
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linagliptin reduced mean HbA1c by
approximately 0.4% (baseline 7.7–8.1%) versus
placebo. Rates of HEs with DPP-4 inhibitors
were not significantly different versus placebo
in any study. Rates of adverse events (AEs) and
changes involving renal function were similar
in the active- and placebo-treated groups.
Conclusion: These results suggest that DPP-4
inhibitors have the potential to improve
glycemic control in patients with RI without
increasing the risk of HEs or overall AEs.
Funding: Novartis Pharma AG.
Keywords: DPP-4 inhibitors; Linagliptin;
Saxagliptin; Sitagliptin; Type 2 diabetes
mellitus; Vildagliptin
INTRODUCTION
Renal impairment (RI) is a common
complication in patients with type 2 diabetes
mellitus (T2DM). Approximately one in every
five patients with T2DM has an estimated
glomerular filtration rate (eGFR) \60 mL/min/
1.73 m2 [1]. Presence and severity of RI in
patients with T2DM are associated with an
increased risk of adverse clinical outcomes,
including hospitalization, cardiovascular
events, heart failure, end-stage renal disease
(ESRD), and premature mortality [2, 3]. Given
this elevated risk, there is a strong exigency to
intervene in patients with RI. Indeed, studies
suggest that a greater reduction in the absolute
risks in this population may be achieved with
intensive treatment of blood pressure or lipid
levels, and fewer patients may need treatment to
prevent one event, compared with individuals
with normal renal function who required
treatment [4, 5]. However, intensive control of
blood glucose levels in patients with T2DM and
RI is challenging and often regarded as
problematic, which also compromises glycemic
control leading to therapeutic inertia. A robust
association exists between glycated hemoglobin
(HbA1c) and clinical outcomes in patients with
RI [2]; however, in patients with T2DM, presence
of RI is associated with an increase in the risk of
adverse events (AEs) such as hypoglycemia [6],
gastrointestinal symptoms [7], fluid retention
[8], and bone fracture [9]. In addition, RI directly
or indirectly affects the pharmacokinetics and
pharmacodynamics of several glucose-lowering
agents and demands dose adjustment while
prescribing these agents in patients with RI
[10]. Some glucose-lowering agents such as
sodium glucose cotransporter-2 (SGLT-2)
inhibitors are less effective in patients with RI
[9]. Moreover, a high pill burden and the
challenges of treatment compliance may also
make treatment intensification even more
difficult in patients with RI [11]. Dipeptidyl
peptidase-4 (DPP-4) inhibitors are widely used
in the management of T2DM and have
confirmed efficacy and safety, without
increasing the risk of hypoglycemia and weight
gain in patients with normal renal function [12].
In addition, DPP-4 inhibition has the potential
to address several impediments associated with
intensification of glycemic control in patients
with RI [13]. However, limited data on
comparative efficacy and safety of DPP-4
inhibitors are available, especially in patients
with RI. Consequently in this paper, we report
the findings from a systematic literature review
of the efficacy and safety of DPP-4 inhibitors in
patients with T2DM and RI.
METHODS
Search
We conducted a search of all English language
studies on DPP-4 inhibitors in patients with
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T2DM and RI in the databases EMBASE,
MEDLINE, and the Cochrane Central Register
of Controlled Trials, from database inception to
June 3, 2015. Search terms included population
(diabetes mellitus, type 2 OR diabet*) AND
interventions (vildagliptin, sitagliptin,
saxagliptin, linagliptin, alogliptin, gemigliptin,
or teneligliptin, their associated molecules or
chemical compound/entity names) and
randomized controlled trials using the Scottish
Intercollegiate Guidelines Network
(SIGN)-approved filter. Duplicate publications
were eliminated and eligible records were
screened independently by two reviewers
(from Analysis Group Inc., Boston, MA, USA),
first by title and abstract followed by full text.
The resulting publications were screened further
for studies that were placebo-controlled
randomized clinical trials of C12-week
duration and included C50 patients with
T2DM and RI who had received a DPP-4
inhibitor, with one or more of the following
study outcomes: HbA1c, fasting plasma glucose
(FPG), weight, hypoglycemia and lipid profile
(complete inclusion and exclusion criteria are
shown in Table S1 in the supplementary
material).
Outcomes
The outcomes included changes in HbA1c and
FPG at weeks 12 and 52. Overall safety,
incidence of hypoglycemic events (HEs) and
renal function were also reported.
Additional Analyses
In the vildagliptin studies [14, 15], HbA1c and
FPG outcomes were separately analyzed for
patients with moderate (eGFR, C30 to\50 mL/
min/1.73 m2) and severe RI (eGFR, \30 mL/
min/1.73 m2) by treatment, but not pooled for
overall patients, whereas in sitagliptin [16] and
saxagliptin [17, 18] studies, these outcomes
were not only separately analyzed for patients
with moderate (creatinine clearance [CrCl] C30
to \50 mL/min) and severe RI (CrCl \30 mL/
min and not receiving dialysis) but also pooled
for overall patients based on treatment. For the
present systematic review, an analysis was
performed to determine the weighted
estimated overall mean HbA1c and FPG, so
that the overall data for each vildagliptin study
could be compared with other DPP-4 inhibitors.
In trials which did not report numerical
values for changes in HbA1c and FPG versus
baseline, numerical values were approximated
from graphically presented data by pixel
analysis. Similarly, if the data on
between-treatment differences for changes in
HbA1c and FPG were not available in an
individual publication; descriptive statistics
were used to determine the same. Microsoft
Excel (Microsoft Corporation, Redmond, WA,
USA) was used for all statistical analyses.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RESULTS
Identified Studies
Overall, we identified 4542 studies during the
initial search (Fig. 1), among which 51 studies
were shortlisted following deletion of duplicates
Diabetes Ther (2016) 7:439–454 441
and screening based on titles and abstracts. Of
these 51 studies, 7 studies met the inclusion
criteria during the screening based on full text:
5 were placebo-controlled trials (one each on
vildagliptin [14], sitagliptin [16], and
saxagliptin [17], and two on linagliptin
[19, 20]), and the remaining two were 52-week
extension studies of vildagliptin [15] and
saxagliptin [18]. The study designs of the
studies included in this review are summarized
in the supplementary material (Table S2). There
were no full-text publications available for
gemigliptin, alogliptin, or teneligliptin that
met the inclusion criteria, at the time when
the search was conducted.
Patient Demographics and Baseline
Characteristics
Demographics and baseline characteristics of
patients were broadly similar across treatment
groups and within each study, with mean age
ranging from 64 to 70 years (Table 1). Over 50%
patients across the study groups were men,
except in the saxagliptin study, which had more
women (approximately 62%). Most study
participants were White, except the sitagliptin
study, which had similar proportions of White,
Hispanic/Latino, and Asian participants. The
mean body mass index across the groups was
approximately 30 kg/m2, except in the
sitagliptin group (approximately 27 kg/m2). At
baseline, the mean HbA1c was \8% in the
sitagliptin and vildagliptin studies
(approximately 7.7%), while it was[8% in the
saxagliptin and linagliptin studies (8.1–8.5%).
The mean FPG across the treatment groups
ranged between 8.1 and 10.4 mmol/L, with
highest levels observed in the saxagliptin
group. Patients in the saxagliptin, sitagliptin
and vildagliptin studies had a mean T2DM
duration of C13 years. The disease duration
was markedly different in the linagliptin
study: most patients (placebo group, 97%;
active treatment group, 95.2%) had T2DM for
more than 5 years.
Apart from the sitagliptin study, most
patients in the other studies were on insulin
(53–86%), few received oral antidiabetes drugs
(OADs; 14–35%), and the remaining received
insulin in combination with OADs. However, in
the sitagliptin study, most patients
(approximately 69%) received OADs alone and
only approximately 11% received insulin in the
placebo-controlled phase of the trial. In the
vildagliptin study, almost all patients were on
anti-hypertensive agents that block the
renin–angiotensin–aldosterone system (RAAS).
Fig. 1 PRISMA diagram for study selection. 1 The
following criteria were applied for screening of title/
abstract but did not lead to any exclusions: outcomes, trial
length and comparator arms; 2 the following criteria were
applied for screening of full text but did not lead to any
exclusions: study type, treatment, outcomes, trial length
B12 weeks, and sample size B50; 3 two studies are
extensions of other studies included in the analysis after
screening of full text [15, 18]. Relevant studies that only
report outcomes for renally impaired patients with type 2
diabetes mellitus in the full text may have been excluded if
the title or abstract of the study does not mention this
subpopulation
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Similarly, in the sitagliptin study, the most
frequent concomitant medication was a RAAS
inhibitor ([70%) and in the linagliptin study,
[90% patients were on anti-hypertensive agent.
In the saxagliptin study, use of any
concomitant medications other than
glucose-lowering agents was not reported.
In the sitagliptin study, open-label rescue
therapy (insulin up-titration or initiation of
sulfonylurea or insulin) was available
throughout the study if pre-specified glycemic
control criteria were not met [16]. In the
vildagliptin study, rescue medication, as
insulin addition or intensification was
permitted after 4 weeks if pre-specified
glycemic control criteria were not met
[14, 15]. In the saxagliptin study, patients were
discontinued from the study if pre-specified
glycemic control criteria were not met [17, 18].
In the linagliptin study, stable doses of
background therapy were maintained in the
first 12 weeks of the study, unless dose
adjustments were necessary due to safety
reasons, and in the following 40-week
treatment period, background therapy could
be adjusted according to glucose parameters;
rescue therapy (insulin addition) was allowed
based on failure to meet pre-specified glycemic
response criteria at any time point during the
study [19].
Reduction in HbA1c
In each long-term study, the HbA1c-lowering
effect from a given baseline was similar at weeks
12 and 52 in the overall population (both
moderate and severe RI, Fig. 2a), implying
sustainable effects in this setting. In the
12-week sitagliptin study, a placebo-adjusted
mean HbA1c reduction of 0.4% (baseline, 7.6%;
95% confidence interval [CI], -0.7 to -0.1) was
observed in the overall population [16]. TheT
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placebo-adjusted mean reduction in HbA1c
with vildagliptin was 0.6% (baseline, 7.8%) at
week 12, which was sustained until 52 weeks
[14, 15]. The placebo-adjusted mean reduction
in HbA1c was significantly high in the
saxagliptin group at week 12 (0.42%; baseline,
8.5%; 95% CI, -0.71 to -0.12; P = 0.007) and
week 52 (0.73%; baseline, 8.4%; 95% CI, -1.11
to -0.34; P\0.001) [17, 18]. After 12 weeks, the
placebo-adjusted mean reduction in HbA1c
with linagliptin was 0.42% (95% CI, -0.60 to
-0.24; P\0.0001) [20].
In patients with moderate RI, the
placebo-adjusted mean reduction in HbA1c in
vildagliptin-treated patients at week 12 was
0.63% and at week 52 was 0.4%, which was
statistically significant (P = 0.005; Fig. 2b)
[14, 15]. Similarly, saxagliptin-treated patients
showed numerically higher placebo-adjusted
mean reductions in HbA1c at weeks 12
(0.59%) and 52 (1.13%) [17, 18]. HbA1c data
for sitagliptin- and linagliptin-treated patients
with moderate RI are not available in their
individual publications [16, 19, 20].
In patients with severe RI treated with
vildagliptin, the placebo-adjusted mean
reduction in HbA1c of 0.5% at week 12 and
0.7% (P\0.0001) at week 52 was significant
(Fig. 2c) [14, 15]. Saxagliptin-treated patients
showed a numerically greater reduction in
HbA1c versus placebo of 0.45% and 0.32% at
weeks 12 and 52, respectively [17, 18]. The
between-treatment difference for linagliptin
versus placebo was statistically significant at
weeks 12 (-0.60%; 95% CI, -0.89 to -0.31;
P\0.0001) and 52 (-0.72%; 95% CI, -1.03 to
-0.41; P\0.0001) [19].
cFig. 2 Mean HbA1c levels in patients with T2DM and RI
at weeks 12 and 52. a Overall RI; b moderate RI; and
c severe RI. Data are presented as mean HbA1c levels at
weeks 12 and 52 from the baseline. Cap indicates starting
of baseline values, downward arrow indicates magnitude of
reduction from baseline and upward arrow indicates
magnitude of increase from baseline. ^ Included patients
with moderate RI and severe RI. * Included patients with
moderate RI, severe RI, and ESRD. Overall data for
vildagliptin study was estimated by weighted average mean
of patients with moderate and severe RI. Numerical values
for mean HbA1c levels at week 12 for vildagliptin studies
were approximated from graphically presented data by
pixel analysis. ESRD end-stage renal disease, HbA1c
glycated hemoglobin, LINA linagliptin, PBO placebo, RI
renal impairment, SAXA saxagliptin, SITA sitagliptin,
T2DM type 2 diabetes mellitus, VILDA vildagliptin
Diabetes Ther (2016) 7:439–454 445
Data for patients with ESRD were available
only for the saxagliptin study. At week 12, the
between-group difference in HbA1c was 0.03%
(P value non-significant), and after 52 weeks,
this difference was -0.14% (data not shown)
[17, 18]. There was a modest (0.1–0.2%) but
significantly greater reduction in HbA1c in
patients with severe RI (eGFR, \30 mL/min/
1.73 m2) than in patients with moderate RI
(eGFR, 30–60 mL/min/1.73 m2; P\0.05).
Reduction in FPG
The mean reductions in FPG from baseline at
weeks 12 and 52 in the overall population of
each study are depicted in Fig. 3a; further
stratifications by moderate RI (Fig. 3b) and
severe RI (Fig. 3c) subgroups are also shown. In
the 12-week sitagliptin study, the difference in
FPG between sitagliptin- and placebo-treated
patients was -1.3 mmol/L (95% CI, -2.2 to
-0.3) [16].
Safety and Tolerability
Overall, the incidences of AEs were similar
between the active treatment and placebo
groups across all studies (Table 2). The number
of patients reporting any AE, drug-related AEs,
serious AEs, and AEs leading to treatment
discontinuation in the treatment groups were
broadly similar to that of their corresponding
placebo groups, and AEs were mild to moderate
in severity [14–20].
In every study, the most frequently reported
AE was hypoglycemia (Table 3). For sitagliptin,
during the 12-week, placebo-only controlled
phase of the trial, the incidence of
hypoglycemia was similar between both
cFig. 3 Mean FPG levels in patients with T2DM and RI at
weeks 12 and 52. a Overall RI; b moderate RI; and c severe
RI. Data are presented as mean FPG levels at weeks 12 and
52 from the baseline. Cap indicates starting of baseline
values; downward arrow indicates magnitude of reduction
from baseline; upward arrow indicates magnitude of
increase from baseline. ^ Included patients with moderate
RI and severe RI. * Included patients with moderate RI,
severe RI, and ESRD. Overall data for vildagliptin study
was estimated by weighted average mean of patients with
moderate and severe RI. Numerical values for mean FPG
levels at week 12 for vildagliptin studies were approximated
from graphically presented data by pixel analysis. ESRD
end-stage renal disease, FPG fasting plasma glucose, LINA
linagliptin, PBO placebo, RI renal impairment, SAXA
saxagliptin, SITA sitagliptin, T2DM type 2 diabetes
mellitus, VILDA vildagliptin
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groups (sitagliptin, 4.6% vs. placebo, 3.8%) [16].
In the vildagliptin study, the incidences of
hypoglycemia in the overall population at
weeks 24 and 52 were comparable with
placebo [14, 15]. In patients with moderate RI,
the incidence of HEs was numerically higher in
patients who received active treatment versus
those who received placebo at weeks 24 and 52.
The incidence of severe hypoglycemia was
similar between the treatments (vildagliptin,
1.2% vs. placebo, 1.6%) at week 24 [14]. In the
severe RI group, the incidences of hypoglycemia
were similar with vildagliptin and placebo at
both weeks 24 and 52 [14, 15]. However, the
incidence of severe hypoglycemia was lower
with vildagliptin than placebo at week 52 in
patients with both moderate and severe RI [15].
In the saxagliptin study, the incidences of
hypoglycemia were similar in both active and
placebo groups at weeks 12 and 52 in the overall
population and in patients with moderate RI
and ESRD [17, 18]. However, in patients with
severe RI, the incidence of hypoglycemia in the
saxagliptin-treated patients was almost double
that in the placebo-treated patients at weeks 12
(27.8% vs. 13.0%) and 52 (33.3% vs. 17.4%)
[17, 18]. In the 12-week placebo-controlled
phase, the incidence of hypoglycemia was
comparable between linagliptin and placebo in
the overall population [20]. In another study,
the incidence of hypoglycemia was higher in
linagliptin-treated patients with severe RI than
in placebo-treated patients at weeks 12 and 52;
this was attributed to the higher incidence of
asymptomatic hypoglycemia with linagliptin
[19]. However, the incidence of severe
hypoglycemia was low and similar between
both groups: 4.4% with linagliptin and 4.6%
with placebo [19].
Renal Findings
In the vildagliptin study, there was a slight but
similar decline in eGFR over 52 weeks in both
vildagliptin and placebo groups (moderate RI,
-1.62 vs. -1.80 mL/min; severe RI, -1.98 vs.
-2.44 mL/min, respectively). The mean serum
potassium levels were more or less unchanged
over the course of the year. The incidence of
hyperkalemia was comparable between
vildagliptin- and placebo-treated patients in
both moderate (3.3% vs. 3.4%) and severe RI
(10.6% vs. 6.3%) groups. This incidence was
slightly higher in severe RI group than in
moderate RI group [15]. In the saxagliptin
study, patients with moderate or severe RI
reported a slight decline in eGFR over
52 weeks (details not provided) [18]. The
decline in eGFR in the linagliptin study was
not clinically meaningful in patients with
severe RI [19] and remained stable throughout
the study in overall patients with RI [20]; the
incidence of hyperkalemia was broadly similar
in the linagliptin and placebo groups (30.9% vs.
24.6%) and not judged to be related to the study
drug for the linagliptin group [19]. Neither
eGFR nor hyperkalemia findings were reported
for sitagliptin [16].
DISCUSSION
DPP-4 inhibitor therapies have substantially
contributed to the advancement in the
management of T2DM. However, their greatest
clinical impact may be found in patients in
whom conventional therapy has considerable
limitations leading to therapeutic inertia and/or
compromises in glycemic control. A prime
example has been the use of DPP-4 inhibitors
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in patients with T2DM and RI. In this
systematic literature review, we showed that
DPP-4 inhibitors are both efficacious and well
tolerated in patients with T2DM and RI when
used at appropriate doses or dosing frequencies
based on the severity of RI. These results further
support the use of DPP-4 inhibitors in the
particularly challenging setting of RI.
In all the aforementioned studies, DPP-4
inhibitors in patients with RI reduced HbA1c
levels by 0.4–0.7%, wherein the mean baseline
HbA1c ranged from 7.7% to 8.4%, compared
with placebo at different time points [14–20].
This is comparable to the reductions observed
in placebo-controlled trials in patients with
normal renal function, particularly when
DPP-4 inhibitors were added to pre-existing
[21] and often long-term insulin therapy (the
most common background therapy in studies
included in this analysis). The findings reported
in the present review were in line with a
previously reported systematic review and
meta-analysis of 10 pooled studies conducted
in patients with moderate and severe RI [22].
Notably, a modest (0.1–0.2%) but greater
additional reduction in HbA1c was observed in
patients with severe RI (eGFR, \30 mL/min/
1.73 m2) than in those with moderate RI (eGFR,
30–60 mL/min/1.73 m2; P\0.05). It is possible
to speculate that patients with severe RI may
show a greater increase in glucagon-like
peptide-1 (GLP-1) as its half-life is further
prolonged by reduced renal clearance [23]. In
addition, the reduced half-life of erythrocytes in
patients with severe RI may have
underestimated glycemic control in such
patients than in those with better renal
function [24]. As the effects of DPP-4
inhibition (and incretin effect) on glycemia
are proportionally greater in individuals with
higher baseline glucose levels [25], a greater
reduction in HbA1c may be anticipated in
patients with severe RI who are likely to have
had higher glucose levels despite having
comparable baseline HbA1c levels to those
with moderate RI.
Hypoglycemia, a frequent complication of
diabetes management, affects approximately
25% of patients with T2DM at least once a
year [26]. It is also often an important barrier to
optimized glycemic control [27]. RI is associated
with an increased incidence and severity of HEs
[28]. Indeed, in all studies included in the
present analysis, 1–4% of patients with RI
experienced a severe HE (requiring assistance).
This proportion is 5- to 10-times higher than
that reported in patients with normal renal
function [29], even without adjusting for the
appropriate dose of insulin or insulin
secretagogues in this setting. However, the
addition of DPP-4 inhibitors in this setting
achieved improved glycemic control without
any significant increase in HEs in any individual
study compared with placebo. Moreover, it is
likely that in clinical settings, pre-emptive
down-titration of insulin/sulfonylurea dosage
following improvement in glycemic control
induced by DPP-4 inhibition should result in
even lower rates of hypoglycemia in patients
receiving DPP-4 inhibitors. However, in blinded
placebo-controlled trials, any down-titration is
generally limited and would not occur until the
patient experiences a HE or records lower
glucose levels [14–20].
Moreover, T2DM management in patients
with RI is associated with higher health care
costs and reduced health-related quality of life
[1, 30], which is partly mediated by the presence
and severity of co-morbid diseases and
multi-factorial interventions necessitated by
their presence [30]. In addition, the frequency
and severity of hypoglycemia as well as the risk
of hypoglycemia are critical determinants of
overall health status and mental and physical
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health [31]. Although no economic or quality of
life indices were assessed in the studies included
in this systematic literature review, a previous
study has shown that DPP-4 inhibitors may
improve quality of life indices in patients with
T2DM and normal renal function [32], whereas
the introduction or escalation of insulin
therapy might reduce them. Health-economic
and quality of life studies, specifically in
patients with T2DM and RI receiving DPP-4
inhibitors, are certainly warranted for various
reasons; different dosing frequencies might
have cost implications, and it is well
documented that patients with chronic kidney
disease not only have generally increased costs
but also have a reduced quality of life.
In patients with established RI, avoiding or
slowing a further decline in renal function is a
priority. In the ADVANCE trial
(ClinicalTrials.gov identifier: NCT00145925),
an intensified glycemic control significantly
reduced the number of individuals requiring
renal replacement therapy [33]. Such data
support the renoprotective utility of improved
glycemic control in patients at the risk of ESRD
(i.e., in patients with established RI), provided it
can be safely achieved. Unfortunately, as in the
ADVANCE study (using the sulfonylurea,
gliclazide), the risk of severe hypoglycemia is
often increased after intensification in patients
with RI [34]; hence, the overall balance of risks
and benefits remain unclear. However, the
efficacy and safety of glycemic control with
DPP-4 inhibitors in patients with RI reported in
this analysis should change this balance.
Certain studies have suggested that DPP-4
inhibitors may have renal benefits beyond
glucose lowering [35] and have also reported
modest reductions in albuminuria [36, 37].
However, it is unclear whether this is a valid
marker of renal protection achieved by these
agents. In the SAVOR TIMI-53 study
(ClinicalTrials.gov identifier: NCT01107886),
despite reduction in albuminuria, there was no
difference in ESRD or progressive renal decline
between patients receiving saxagliptin and
those receiving placebo [37]. At present, it can
be concluded that there is no evidence of any
adverse effect on renal function following the
use of DPP-4 inhibitors (i.e., renal safety) in
patients with T2DM and RI [15, 19]. Longer
studies with a focus on renal safety remain to be
completed to establish any renoprotective
effects in addition to glycemic control.
However, fundamentally, for the use of DPP-4
inhibitors in patients with RI, the ability to
safely lower glucose levels is the primary
attribute and indication.
CONCLUSIONS
In summary, for patients with T2DM and RI,
diabetes management is complex,
multi-dimensional and potentially expensive.
Our systematic review suggests that DPP-4
inhibitors have the potential to improve and
simplify glycemic control in this setting without
exposure to hypoglycemia or other important
AEs. The renoprotective potential of DPP-4
inhibitors remains unproven, but is a subject of
ongoing investigations in clinical trials. Since
improved glycemic control has been shown to
reduce the risk of ESRD, safe and optimum
control in patients with RI would also have
additional renal benefits. Given the high
financial burden and reduced quality of life of
patients with T2DM and RI, further economic
and quality of life analyses are warranted.
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